Tangier disease: update for 2020

被引:27
|
作者
Hooper, Amanda J. [1 ,2 ,3 ]
Hegele, Robert A. [4 ,5 ,6 ]
Burnett, John R. [1 ,2 ,3 ]
机构
[1] Royal Perth Hosp, Dept Clin Biochem, PathWest Lab Med WA, Perth, WA, Australia
[2] Fiona Stanley Hosp Network, Perth, WA, Australia
[3] Univ Western Australia, Fac Hlth & Med Sci, Sch Med, Perth, WA, Australia
[4] Western Univ, Schulich Sch Med, Dept Med, London, ON, Canada
[5] Western Univ, Schulich Sch Med, Dept Biochem, London, ON, Canada
[6] Western Univ, Robarts Res Inst, London, ON, Canada
关键词
ABCA1; low HDL-cholesterol; tangier disease; CHOLESTEROL EFFLUX; ABCA1; MUTATION;
D O I
10.1097/MOL.0000000000000669
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purpose of reviewTo appraise recent advances in our knowledge of the severe genetic HDL deficiency disorder, Tangier disease.Recent findingsWhile Tangier disease can cause premature atherosclerotic cardiovascular disease (ASCVD), new evidence suggests that heterozygous ABCA1 variant carriers are also at increased risk. Advances have been made in the study of the neurological abnormalities observed in Tangier disease, both in their assessment and the identification of potential new therapies.SummaryTangier disease is an extremely rare condition and, as such, the published literature around its range of clinical manifestations, including peripheral neuropathy, premature ASCVD and platelet abnormalities is limited. Patient registries may assist in this regard.
引用
收藏
页码:80 / 84
页数:5
相关论文
共 50 条
  • [21] Intestinal stricture in Crohn's disease: A 2020 update
    Lin, Xiao Xuan
    Qiu, Yun
    Zhuang, Xiao Jun
    Liu, Fen
    Wu, Xiao Min
    Chen, Min Hu
    Mao, Ren
    JOURNAL OF DIGESTIVE DISEASES, 2021, 22 (07) : 390 - 398
  • [22] Current Diagnosis and Management of Tangier Disease
    Koseki, Masahiro
    Yamashita, Shizuya
    Ogura, Masatsune
    Ishigaki, Yasushi
    Ono, Koh
    Tsukamoto, Kazuhisa
    Hori, Mika
    Matsuki, Kota
    Yokoyama, Shinji
    Harada-Shiba, Mariko
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2021, 28 (08) : 802 - 810
  • [23] Tangier disease with unusual clinical manifestations
    Kolovou, GD
    Wade, DP
    Sengupta, R
    Cokkinos, DV
    CLINICAL GENETICS, 2003, 63 (04) : 323 - 324
  • [24] Update Kardiologie 2020Cardiology update 2020
    Michael Lehrke
    Der Diabetologe, 2020, 16 (5): : 461 - 469
  • [25] Neuropathy in Tangier disease mimicking leprosy
    Garcia-Sobrino, T.
    Rabunal, M. J.
    Beiras, A.
    Lema, M.
    Montiel, M. D.
    Pardo, J.
    JOURNAL OF NEUROLOGY, 2014, 261 : S98 - S98
  • [26] NATURE OF ALPHA LIPOPROTEINS IN TANGIER DISEASE
    LEVY, RI
    FREDRICK.DS
    CIRCULATION, 1966, 34 (4S3) : I156 - &
  • [27] TANGIER DISEASE - AN UNUSUAL DIAGNOSIS FOR THE ENDOSCOPIST
    FROSINI, G
    MARINI, M
    GALGANI, P
    CARNICELLI, N
    FARNETANI, L
    PETTORALI, M
    ENDOSCOPY, 1994, 26 (04) : 373 - 373
  • [28] Tangier Disease Epidemiology, Pathophysiology, and Management
    Puntoni, Mariarita
    Sbrana, Francesco
    Bigazzi, Federico
    Sampietro, Tiziana
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2012, 12 (05) : 303 - 311
  • [29] A novel therapeutic strategy for Tangier disease
    Uehara, Y.
    Zhang, B.
    Tsuboi, Y.
    Miura, S.
    Abe, S.
    Higuchi, M.
    Urata, H.
    Rye, K. A.
    Yamada, T.
    Saku, K.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 562 - 562
  • [30] Tangier disease and ABCA1
    Oram, JF
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2000, 1529 (1-3): : 321 - 330